Stoke Therapeutics (NASDAQ:STOK) said its Phase III EMPEROR study of zorevunersen for Dravet syndrome has enrolled 162 patients, exceeding its target enrollment of 150, with no patient discontinuations reported to date. Speaking at a Canaccord Genuity event, Chief Executive Officer Ian Smith said t

Investing.com -- Wolfe Research upgraded two major pharmaceutical companies to Outperform on Thursday, citing stronger growth prospects, attractive valuations and a series of upcoming clinical catalysts.

Growth portfolio revenue surpassed legacy MS franchise for second consecutive quarter.

Biogen is one of the oldest and most venerable biotechs. For a time in the late 1990s, Biogen's share price grew ninefold.

Amgen, Pfizer, Eli Lilly, Merck and Novo Nordisk are set to report Q2 results this week after a strong start for pharma earnings. Which names could beat forecasts?

Medical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.

Biotech company Biogen (NASDAQ:BIIB) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 3.4% year on year to $2.74 billion. Its non-GAAP profit of $3.60 per share was 75.8% above analysts’ consensus estimates.

The biotech's shares have stumbled after a guidance change, and investors are weighing whether this is the moment to step in or step aside.

Biogen Inc. has released its second-quarter 2026 results, reporting revenue of US$2.74 billion versus US$2.65 billion a year earlier, while net income dropped to US$97.5 million and diluted EPS from continuing operations fell to US$0.66 from US$4.33. Despite modest revenue growth for both the quarter and first half of 2026, Biogen’s profitability compressed sharply, with six‑month net income falling to US$417.0 million from US$875.3 million, highlighting a widening gap between sales...

The company published its second-quarter results on Wednesday morning.